• / Free eNewsletters & Magazine
  • / My Account
Home>Funds>iShares Nasdaq Biotechnology

iShares Nasdaq Biotechnology

iShares Nasdaq Biotechnology IBB 4 Star

Last Price$290.54Day Change (%)0.05%
Open Price$290.52Day Change ($)0.15
Day Range288.85–291.1752-Week Range240.30–303.74

As of Mon 5/22/2017 4:05:00 PM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Exact Sciences CEO and short-seller go mano-a-mano on CNBC, stock pares losses

    Exact Sciences CEO and short-seller go mano-a-mano on CNBC, stock pares losses

  2. Capricor's stock tumbles toward record low after disappointing trial results

    Capricor's stock tumbles toward record low after disappointing trial results

  3. Ziopharm Oncology's stock tumbles after stock offering prices at deep discount

    Ziopharm Oncology's stock tumbles after stock offering prices at deep discount

  4. How to make money as the 'disenchanted' middle class changes politics

    How to make money as the 'disenchanted' middle class changes politics

  5. Hagens Berman Notifies BlackRock ETF Investors of Court Ruling Upholding August 24, 2015 ETF Flash Crash Case and Scheduling Hearing

    Hagens Berman Notifies BlackRock ETF Investors of Court Ruling Upholding August 24, 2015 ETF Flash Crash Case and Scheduling Hearing

  6. UPDATE: Bill Gates tells new grads to read this book that says the world is getting better

    UPDATE: Bill Gates tells new grads to read this book that says the world is getting better

  7. Bill Gates tells new grads to read this book that says the world is getting better

    Bill Gates tells new grads to read this book that says the world is getting better

  8. An ETF for This Lagging Sector

    Biotech companies' returns have diverged from the broader market in recent weeks amid concerns over greater regulation and price discounting.

  9. Where Are the Opportunities in U.S. Health Care?

    As the sector has continued to best the broader market, a look both at the dynamics that would drive further outperformance by the sector and at funds that investors can use to tap those themes.

  10. Why the Short-Term Tumult?

    This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...

12

©2017 Morningstar Advisor. All right reserved.